Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

272.98 +1.80 (+0.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Amgen Expands US Manufacturing Network Amid New Tariff Policy
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network. 
Via Benzinga
Topics Government World Trade
Amgen Announces $650M Expansion Of US Manufacturing Network After Trump’s Pharma Tariff Announcement
Via Stocktwits
Topics Government
How Is The Market Feeling About Amgen?
 
Via Benzinga
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug
Via Stocktwits
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
The Analyst Verdict: Amgen In The Eyes Of 8 Experts
8 analysts have shared their evaluations of Amgen (NASDAQ: AMGN) during the recent three months, expressing a mix of bullish and bearish perspectives. 
Via Benzinga
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results. 
Via Benzinga
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity... 
Via MarketMinute
Topics Economy
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Why Amgen (AMGN) Stock Is Trading Up Today
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder. 
Via StockStory
Topics Artificial Intelligence
Friday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle
The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like... 
Via MarketMinute
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
EMA Backs Amgen Drug For Rare Autoimmune Disorder
European Medicines Agency's panel recommends expanding Amgen's Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates. 
Via Benzinga
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. 
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
2 Healthcare Dividend Stocks to Buy and Hold
These drugmakers have competitive yields and have increased their dividends at a good clip. 
Via The Motley Fool
Topics Intellectual Property
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
1 Cash-Producing Stock to Target This Week and 2 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients. 
Via Benzinga
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today
You could have done worse -- or much better. 
Via The Motley Fool
Topics Economy
Nvidia Just Went Quantum—And ETFs Are Scrambling To Catch Up
Nvidia's $600M investment in Quantinuum highlights quantum computing's commercial evolution and may prompt new ETF strategies in the coming years. 
Via Benzinga
Topics ETFs
Why Is Sanofi Stock Falling Thursday?
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. 
Via Benzinga
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.